New drug information: Besivance.
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001381:Azepines / Q000494:pharmacology / Q000627:therapeutic use*; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy*; D024841:Fluoroquinolones / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009883:Ophthalmic Solutions; D059005:Topoisomerase II Inhibitors
D000900:Anti-Bacterial Agents; D001381:Azepines; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D059005:Topoisomerase II Inhibitors; C522124:besifloxacin